Our Insights Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More Oncology Anthony Iannacci 10/3/22 Oncology Anthony Iannacci 10/3/22 CAR-T Outlook Read More
Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More
Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More
